Neurocrine Biosciences (NASDAQ: NBIX) reported Q3 EPS of $1.08, $0.28 better than the analyst estimate of $0.80. Revenue for the quarter came in at $387.9 million versus the consensus estimate of $376.55 million.

For earnings history and earnings-related data on Neurocrine Biosciences (NBIX) click here.